Trevi Therapeutics, Inc. (TRVI): Price and Financial Metrics

Trevi Therapeutics, Inc. (TRVI): $2.24

0.06 (+2.75%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

D

TRVI Price/Volume Stats

Current price $2.24 52-week high $3.50
Prev. close $2.18 52-week low $1.43
Day low $2.20 Volume 3,956
Day high $2.24 Avg. volume 172,147
50-day MA $2.26 Dividend yield N/A
200-day MA $2.33 Market Cap 143.03M

TRVI Stock Price Chart Interactive Chart >


Trevi Therapeutics, Inc. (TRVI) Company Bio


Trevi Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of treatment for neurologically mediated conditions. It focuses on the formulation of nalbuphine ER, which use to treat chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good on March 17, 2011 and is headquartered in New Haven, CT.


TRVI Latest News Stream


Event/Time News Detail
Loading, please wait...

TRVI Latest Social Stream


Loading social stream, please wait...

View Full TRVI Social Stream

Latest TRVI News From Around the Web

Below are the latest news stories about TREVI THERAPEUTICS INC that investors may wish to consider to help them evaluate TRVI as an investment opportunity.

Trevi Therapeutics (NASDAQ:TRVI) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Yahoo | August 12, 2023

Q2 2023 Trevi Therapeutics Inc Earnings Call

Q2 2023 Trevi Therapeutics Inc Earnings Call

Yahoo | August 11, 2023

Trevi Therapeutics Announces Second Quarter 2023 Financial Results and Provides Business Update

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for difficult to treat patients with chronic cough in idiopathic pulmonary fibrosis (IPF), other chronic cough indications, and prurigo nodularis, today announced financial results for the quarter ended June 30, 2023, as well as provided business updates.

Yahoo | August 10, 2023

Trevi Therapeutics to Report Q2 2023 Financial Results and Provide a Corporate Update on August 10, 2023

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for difficult to treat patients with chronic cough in idiopathic pulmonary fibrosis (IPF), other chronic cough indications, and prurigo nodularis, today announced that senior management will host a conference call and live audio webcast on Thursday, August 10, 2023, at 4:30 p.m. ET, to provide a corporate update and review the Company's financia

Yahoo | August 3, 2023

Trevi Therapeutics to Participate in Upcoming August Events

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for difficult to treat patients with chronic cough in idiopathic pulmonary fibrosis (IPF), other chronic cough indications, and prurigo nodularis, today announced senior management will attend and participate in the following events in August.

Yahoo | August 1, 2023

Read More 'TRVI' Stories Here

TRVI Price Returns

1-mo -0.88%
3-mo -1.75%
6-mo 21.08%
1-year 28.00%
3-year -42.56%
5-year N/A
YTD 16.06%
2022 146.74%
2021 -67.68%
2020 -35.47%
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!